Table 3.

TP53 status in CLL patients with p53 dysfunction

CaseBase changePredicted codon change
63-150 None None 
83-150 None None  
93-151 413 C→T (exon 5) 138 A→V  
103-151 430 C→T (exon 5) 144 Q→stop  
113-151 584 T→A (exon 6) 195 I→N 
123-151 764 T→A (exon 7) 255 I→N 
193-150 None None  
243-150 None None 
353-150 None None  
363-150 None None 
393-151 743 G→A (exon 7) 248 R→Q 
403-150 None None  
423-151 673-681 del 9nt del 225-227 V,G,S 
CaseBase changePredicted codon change
63-150 None None 
83-150 None None  
93-151 413 C→T (exon 5) 138 A→V  
103-151 430 C→T (exon 5) 144 Q→stop  
113-151 584 T→A (exon 6) 195 I→N 
123-151 764 T→A (exon 7) 255 I→N 
193-150 None None  
243-150 None None 
353-150 None None  
363-150 None None 
393-151 743 G→A (exon 7) 248 R→Q 
403-150 None None  
423-151 673-681 del 9nt del 225-227 V,G,S 

All 13 patients with type B

F3-150

or A

F3-151

p53 dysfunction were subjected to TP53 mutation analysis. The entire coding region was sequenced in both orientations from a combination of genomic PCR and RT-PCR products, as detailed in “Patients, materials, and methods.” Nucleotide positions relate to cDNA and are numbered from the ATG codon.

Close Modal

or Create an Account

Close Modal
Close Modal